Concepedia

Donald B. Axworthy

DB

27

Publications

2K

Citations

24

H-Index

1984

Active since

Affiliations

University of Washington(Current)

Fred Hutch Cancer Center

National Cancer Institute

Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Immunovaccine (Canada)

Donald B. Axworthy is an author at University of Washington specializing in medicine, immunology, and oncology.

Top concepts

MedicineOncologyImmunologyPharmacologyRadiation OncologyImmunotherapyCancer ResearchNatural SciencesTumor MicroenvironmentBiochemistry

Publications per year

1984–2019

27

Publications

27

Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity

Donald B. Axworthy, J. M. Reno, Mark D. Hylarides et al. · Proceedings of the National Academy of Sciences · 2000 · 230 citations · Full text

Colon Cancer Xenografts, Immunology, 600-800 Microci +17

Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.

SJ Knox, Michael L. Goris, Margaret A. Tempero et al. · PubMed · 2000 · 212 citations

Immunology, Gastroenterology, Pathology +16

Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin.

Hazel B. Breitz, Paul L. Weiden, Paul L. Beaumier et al. · PubMed · 2000 · 151 citations

Engineering, Evaluated.the Optimal Schema, Immunology +17

A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy.

Jody Schultz, Yukang Lin, James Sanderson et al. · PubMed · 2000 · 127 citations

Engineering, B9e9 Monoclonal Antibody, Immunology +21

In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.

Michael R. Lewis, Mu Wang, Donald B. Axworthy et al. · PubMed · 2003 · 110 citations

Rows per page

1–5 of 27